2025 Q3 -tulosraportti
Vain PDF
83 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
4 219
Myynti
Määrä
7 366
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 467 | - | - | ||
| 815 | - | - | ||
| 100 | - | - | ||
| 723 | - | - | ||
| 154 | - | - |
Ylin
6,625VWAP
Alin
6,2VaihtoMäärä
3,1 491 928
VWAP
Ylin
6,625Alin
6,2VaihtoMäärä
3,1 491 928
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 232 068 | 232 068 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 232 068 | 232 068 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 27.5.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
1 päivä sitten1 päivä sittenJust a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.
·1 päivä sittenDisagree with you that it is irresponsible to say one should hold. There are probably no players now who have subscription rights below the current valuation? Other than possibly primary insiders who have options, but they are under lockup. Personally, I have great faith in this company, the fundamental conditions have never been better, several of the major risk factors have been mitigated. And awaiting CU/EAP data, as well as strong hints from a usually modest management about a possible deal, I dare not risk being on the sidelines. In my mind, the two biggest risk factors as of today are whether the effect is good enough, which we will probably get a new indication (but not a final answer) of during Q1 when CU/EAP data is released. The second risk factor comes from the current share price development which could affect the financing solution. It may well be that this will continue to go down for a while longer, "only time will show". Personally, I add to my position when I can and eagerly await the years to come. Where it stands in the meantime, I'll just have to take as it comes.
·1 päivä sittenIt seems from the posts that some of you are trying to push the price down by being negative. Fortunately, it doesn't affect most of us who are long-term investors. Have been involved for many years and have great faith that the upturns are not over💪👍·1 päivä sittenYou exaggerate the importance - and the reason - for more balanced perspectives on Cereno. I don't think anyone is trying to push down the price, rather to provide a counterweight to the uncritical comments. I have been with Cereno since 2023 based on the research. Still believe in the research but think the management is too passive. Received a lot of pushback when I predicted a price decline in October for the coming quarter due to lack of activity (deal). Now we are here.
·2 päivää sitten · MuokattuThe support at 6.30 does not seem to hold, and I am very worried about the price development right now. You should be prepared that the probability is increasing that we may soon see levels around 5 kr, which I have mentioned earlier. It is also not impossible that the price may approach 4 kr shortly.·1 päivä sittenNo one has said that there is no factual information. Where have I written that? What I am pointing out is something completely different: the atmosphere. When the discussion is solely about positive speculations, potential partnerships and “soon-it-will-happen” scenarios, then it's okay. But as soon as someone raises risks, missed results or questions timelines, then warnings and blockings appear. It is that double standard I criticize. Throughout last year, the narrative has revolved around an upcoming deal, a big partnership, a breakthrough around the corner. None of that has happened. It is not “hate” to state that – it is a fact. When hopes are consistently presented as an imminent reality without being delivered, it affects credibility. And when the head administrator in Discord connected to Cereno Scientific also has a history of insider-related issues, then it is reasonable to ask questions about judgment and transparency. It's not about me – it's about trust. A serious forum can handle both optimism and critical scrutiny. If only one side is tolerated, it's not a discussion – it's an echo chamber, but perhaps you don't know what an echo chamber is....
·1 päivä sitten · MuokattuOkay 1. I, including several others, hoped for a deal during the autumn. It didn't happen for various reasons. This meant that those who are after quick cash have started to leave the boat. Everyone does as they please. I think that we long-term investors who remain have every right to believe that a deal will come soon. "Soon" is quite a relative concept depending on who you ask. 2. No individual is above the company and the company's research. 3. It's a shame if you were blocked or similar. What I can say from my experience in Discord is that some individuals have asked critical questions, which is great. The problem is that when they get a thorough answer, they continue with mudslinging. I'm not saying it's you, but I don't think people were kicked out because they don't agree with what most people do. I think we close this discussion here and now. I wish you good luck with your investments.- ·12.2.I am completely convinced that we will see 5:- before Q1 is over, unfortunately.
·8.2.Advancement for Cereno Scientific and candidate CS1 The Expanded Access Program (EAP) has now concluded after the last patient completed their last visit. This provides the company with access to valuable long-term data that complements the promising signals of "reverse vascular remodeling" observed in phase IIa. The insights from the EAP will now pave the way for the next major development step: a global phase IIb study with planned recruitment start in Q2 2026. 💬 – Reaching last patient last visit in the EAP is an important milestone, says CEO Sten R. Sörensen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
83 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten1 päivä sittenJust a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.·1 päivä sittenDisagree with you that it is irresponsible to say one should hold. There are probably no players now who have subscription rights below the current valuation? Other than possibly primary insiders who have options, but they are under lockup. Personally, I have great faith in this company, the fundamental conditions have never been better, several of the major risk factors have been mitigated. And awaiting CU/EAP data, as well as strong hints from a usually modest management about a possible deal, I dare not risk being on the sidelines. In my mind, the two biggest risk factors as of today are whether the effect is good enough, which we will probably get a new indication (but not a final answer) of during Q1 when CU/EAP data is released. The second risk factor comes from the current share price development which could affect the financing solution. It may well be that this will continue to go down for a while longer, "only time will show". Personally, I add to my position when I can and eagerly await the years to come. Where it stands in the meantime, I'll just have to take as it comes.
- ·1 päivä sittenIt seems from the posts that some of you are trying to push the price down by being negative. Fortunately, it doesn't affect most of us who are long-term investors. Have been involved for many years and have great faith that the upturns are not over💪👍·1 päivä sittenYou exaggerate the importance - and the reason - for more balanced perspectives on Cereno. I don't think anyone is trying to push down the price, rather to provide a counterweight to the uncritical comments. I have been with Cereno since 2023 based on the research. Still believe in the research but think the management is too passive. Received a lot of pushback when I predicted a price decline in October for the coming quarter due to lack of activity (deal). Now we are here.
- ·2 päivää sitten · MuokattuThe support at 6.30 does not seem to hold, and I am very worried about the price development right now. You should be prepared that the probability is increasing that we may soon see levels around 5 kr, which I have mentioned earlier. It is also not impossible that the price may approach 4 kr shortly.·1 päivä sittenNo one has said that there is no factual information. Where have I written that? What I am pointing out is something completely different: the atmosphere. When the discussion is solely about positive speculations, potential partnerships and “soon-it-will-happen” scenarios, then it's okay. But as soon as someone raises risks, missed results or questions timelines, then warnings and blockings appear. It is that double standard I criticize. Throughout last year, the narrative has revolved around an upcoming deal, a big partnership, a breakthrough around the corner. None of that has happened. It is not “hate” to state that – it is a fact. When hopes are consistently presented as an imminent reality without being delivered, it affects credibility. And when the head administrator in Discord connected to Cereno Scientific also has a history of insider-related issues, then it is reasonable to ask questions about judgment and transparency. It's not about me – it's about trust. A serious forum can handle both optimism and critical scrutiny. If only one side is tolerated, it's not a discussion – it's an echo chamber, but perhaps you don't know what an echo chamber is....·1 päivä sitten · MuokattuOkay 1. I, including several others, hoped for a deal during the autumn. It didn't happen for various reasons. This meant that those who are after quick cash have started to leave the boat. Everyone does as they please. I think that we long-term investors who remain have every right to believe that a deal will come soon. "Soon" is quite a relative concept depending on who you ask. 2. No individual is above the company and the company's research. 3. It's a shame if you were blocked or similar. What I can say from my experience in Discord is that some individuals have asked critical questions, which is great. The problem is that when they get a thorough answer, they continue with mudslinging. I'm not saying it's you, but I don't think people were kicked out because they don't agree with what most people do. I think we close this discussion here and now. I wish you good luck with your investments.
- ·12.2.I am completely convinced that we will see 5:- before Q1 is over, unfortunately.
- ·8.2.Advancement for Cereno Scientific and candidate CS1 The Expanded Access Program (EAP) has now concluded after the last patient completed their last visit. This provides the company with access to valuable long-term data that complements the promising signals of "reverse vascular remodeling" observed in phase IIa. The insights from the EAP will now pave the way for the next major development step: a global phase IIb study with planned recruitment start in Q2 2026. 💬 – Reaching last patient last visit in the EAP is an important milestone, says CEO Sten R. Sörensen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
4 219
Myynti
Määrä
7 366
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 467 | - | - | ||
| 815 | - | - | ||
| 100 | - | - | ||
| 723 | - | - | ||
| 154 | - | - |
Ylin
6,625VWAP
Alin
6,2VaihtoMäärä
3,1 491 928
VWAP
Ylin
6,625Alin
6,2VaihtoMäärä
3,1 491 928
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 232 068 | 232 068 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 232 068 | 232 068 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 27.5.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
2025 Q3 -tulosraportti
Vain PDF
83 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2027 Q1 -tulosraportti 27.5.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 22.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 | ||
2024 Q3 -tulosraportti 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 1 päivä sitten1 päivä sittenJust a sad look for Cereno right now. The people spouting utter nonsense about the 10SEK valuation being justified and holding should be ashamed. It was always going to happen - small cap biotech just happens to live off of hype and news. When there is none and progress is slow, volume dies down and so does appreciation. Insert a couple of big players with exercisable warrants at cheaper than valuation cost and some others who are selling out of impatience or wanting to realize their gains and you have what we see here - a 30% valuation drop that won‘t be recovered for a while most likely. The future isn‘t all bleak. Of course not. The product has potential and new topline results etc. (if positive) will send this flying back up. Until then, we just have to hold on for the ride. There‘s no regulatory or financial reason for this to go „tits up“ right now, so no reason to panic. Where the evaluation ends up is purely speculative however.·1 päivä sittenDisagree with you that it is irresponsible to say one should hold. There are probably no players now who have subscription rights below the current valuation? Other than possibly primary insiders who have options, but they are under lockup. Personally, I have great faith in this company, the fundamental conditions have never been better, several of the major risk factors have been mitigated. And awaiting CU/EAP data, as well as strong hints from a usually modest management about a possible deal, I dare not risk being on the sidelines. In my mind, the two biggest risk factors as of today are whether the effect is good enough, which we will probably get a new indication (but not a final answer) of during Q1 when CU/EAP data is released. The second risk factor comes from the current share price development which could affect the financing solution. It may well be that this will continue to go down for a while longer, "only time will show". Personally, I add to my position when I can and eagerly await the years to come. Where it stands in the meantime, I'll just have to take as it comes.
- ·1 päivä sittenIt seems from the posts that some of you are trying to push the price down by being negative. Fortunately, it doesn't affect most of us who are long-term investors. Have been involved for many years and have great faith that the upturns are not over💪👍·1 päivä sittenYou exaggerate the importance - and the reason - for more balanced perspectives on Cereno. I don't think anyone is trying to push down the price, rather to provide a counterweight to the uncritical comments. I have been with Cereno since 2023 based on the research. Still believe in the research but think the management is too passive. Received a lot of pushback when I predicted a price decline in October for the coming quarter due to lack of activity (deal). Now we are here.
- ·2 päivää sitten · MuokattuThe support at 6.30 does not seem to hold, and I am very worried about the price development right now. You should be prepared that the probability is increasing that we may soon see levels around 5 kr, which I have mentioned earlier. It is also not impossible that the price may approach 4 kr shortly.·1 päivä sittenNo one has said that there is no factual information. Where have I written that? What I am pointing out is something completely different: the atmosphere. When the discussion is solely about positive speculations, potential partnerships and “soon-it-will-happen” scenarios, then it's okay. But as soon as someone raises risks, missed results or questions timelines, then warnings and blockings appear. It is that double standard I criticize. Throughout last year, the narrative has revolved around an upcoming deal, a big partnership, a breakthrough around the corner. None of that has happened. It is not “hate” to state that – it is a fact. When hopes are consistently presented as an imminent reality without being delivered, it affects credibility. And when the head administrator in Discord connected to Cereno Scientific also has a history of insider-related issues, then it is reasonable to ask questions about judgment and transparency. It's not about me – it's about trust. A serious forum can handle both optimism and critical scrutiny. If only one side is tolerated, it's not a discussion – it's an echo chamber, but perhaps you don't know what an echo chamber is....·1 päivä sitten · MuokattuOkay 1. I, including several others, hoped for a deal during the autumn. It didn't happen for various reasons. This meant that those who are after quick cash have started to leave the boat. Everyone does as they please. I think that we long-term investors who remain have every right to believe that a deal will come soon. "Soon" is quite a relative concept depending on who you ask. 2. No individual is above the company and the company's research. 3. It's a shame if you were blocked or similar. What I can say from my experience in Discord is that some individuals have asked critical questions, which is great. The problem is that when they get a thorough answer, they continue with mudslinging. I'm not saying it's you, but I don't think people were kicked out because they don't agree with what most people do. I think we close this discussion here and now. I wish you good luck with your investments.
- ·12.2.I am completely convinced that we will see 5:- before Q1 is over, unfortunately.
- ·8.2.Advancement for Cereno Scientific and candidate CS1 The Expanded Access Program (EAP) has now concluded after the last patient completed their last visit. This provides the company with access to valuable long-term data that complements the promising signals of "reverse vascular remodeling" observed in phase IIa. The insights from the EAP will now pave the way for the next major development step: a global phase IIb study with planned recruitment start in Q2 2026. 💬 – Reaching last patient last visit in the EAP is an important milestone, says CEO Sten R. Sörensen.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
4 219
Myynti
Määrä
7 366
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 467 | - | - | ||
| 815 | - | - | ||
| 100 | - | - | ||
| 723 | - | - | ||
| 154 | - | - |
Ylin
6,625VWAP
Alin
6,2VaihtoMäärä
3,1 491 928
VWAP
Ylin
6,625Alin
6,2VaihtoMäärä
3,1 491 928
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 232 068 | 232 068 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 232 068 | 232 068 | 0 | 0 |